PharmacyCodes



Alopurinol [Inn-Spanish] en es it fr

Categorie

Alopurinol [Inn-Spanish] Les marques, Alopurinol [Inn-Spanish] Analogs

Alopurinol [Inn-Spanish] Les marques melange

  • No information avaliable

    • Alopurinol [Inn-Spanish] Formule chimique

    C5H4N4O

    Alopurinol [Inn-Spanish] RX lien

    http://www.rxlist.com/cgi/generic/allopur.htm

    Alopurinol [Inn-Spanish] FDA fiche

    http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=133

    Alopurinol [Inn-Spanish] msds (fiche de securite des materiaux)

    Alopurinol_[Inn-Spanish] MSDS

    Alopurinol [Inn-Spanish] Synthese de reference

    Robins, J. Am. Chem. Alors. 78, 784 (1956)

    Alopurinol [Inn-Spanish] Poids moleculaire

    136.112 g/mol

    Alopurinol [Inn-Spanish] Point de fusion

    350 oC

    Alopurinol [Inn-Spanish] H2O Solubilite

    569 mg / L

    Alopurinol [Inn-Spanish] Etat

    Solid

    Alopurinol [Inn-Spanish] LogP

    -0.177

    Alopurinol [Inn-Spanish] Formes pharmaceutiques

    Tablette pour administration orale (100mg, 200mg et 300mg); Injection

    Alopurinol [Inn-Spanish] Indication

    Pour le traitement de l'hyperuricémie associée à la goutte primaire ou secondaire.

    Alopurinol [Inn-Spanish] Pharmacologie

    Allopurinol, un analogue structural de l'hypoxanthine naturels base purique, est utilisé pour prévenir la goutte et des calculs rénaux en raison soit de l'acide urique ou d'oxalate de calcium et de traiter la néphropathie acide urique, une hyperuricémie, et certaines tumeurs solides.

    Alopurinol [Inn-Spanish] Absorption

    Environ 90% absorbés par le tractus gastro-intestinal.

    Alopurinol [Inn-Spanish] Toxicite

    DL50 = 214 mg / kg (chez la souris)

    Alopurinol [Inn-Spanish] Information pour les patients

    Patients should be informed of the following:

    1. They should be cautioned to discontinue allopurinol and to consult their physician immediately at the first sign of a skin rash, painful urination, blood in the urine, irritation of the eyes, or swelling of the lips or mouth.
    2. They should be reminded to continue drug therapy prescribed for gouty attacks since optimal benefit of allopurinol may be delayed for two to six weeks.
    3. They should be encouraged to increase fluid intake during therapy to prevent renal stones.
    4. If a single dose of allopurinol is occasionally forgotten, there is no need to double the dose at the next scheduled time.
    5. There may be certain risks associated with the concomitant use of allopurinol and dicumarol, sulfinpyrazone, mercaptopurine, azathioprine, ampicillin, amoxicillin and thiazide diuretics, and they should follow the instructions of their physician.
    6. Due to the occasional occurrence of drowsiness, patients should take precautions when engaging in activities where alertness is mandatory.
    7. Patients may wish to take allopurinol after meals to minimize gastric irritation.

    Alopurinol [Inn-Spanish] Organismes affectes

    Les humains et autres mammifères